Fox Run Management L.L.C. Takes Position in Stryker Corporation $SYK

Fox Run Management L.L.C. bought a new position in shares of Stryker Corporation (NYSE:SYK) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 6,208 shares of the medical technology company’s stock, valued at approximately $2,295,000. Stryker accounts for approximately 0.4% of Fox Run Management L.L.C.’s investment portfolio, making the stock its 14th largest holding.

Several other institutional investors have also added to or reduced their stakes in SYK. Brighton Jones LLC lifted its holdings in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. bought a new position in Stryker during the second quarter worth about $205,000. Envestnet Asset Management Inc. raised its stake in Stryker by 0.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 634,181 shares of the medical technology company’s stock worth $250,901,000 after purchasing an additional 2,001 shares in the last quarter. Solstein Capital LLC bought a new stake in Stryker in the 2nd quarter valued at about $43,000. Finally, Rossby Financial LCC grew its position in shares of Stryker by 40.6% during the 2nd quarter. Rossby Financial LCC now owns 308 shares of the medical technology company’s stock worth $122,000 after purchasing an additional 89 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

Stryker stock opened at $381.84 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87. The stock has a market capitalization of $146.13 billion, a P/E ratio of 45.46, a price-to-earnings-growth ratio of 2.25 and a beta of 0.87. The stock has a fifty day moving average of $361.24 and a 200-day moving average of $368.91.

Stryker (NYSE:SYK) last released its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The firm had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.01 earnings per share. On average, sell-side analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio is currently 41.90%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 5.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on SYK shares. William Blair began coverage on shares of Stryker in a research report on Friday. They issued an “outperform” rating for the company. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a report on Friday, November 14th. Citizens Jmp raised Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price on the stock in a report on Friday, December 19th. Needham & Company LLC raised their price target on Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Finally, The Goldman Sachs Group set a $399.00 price objective on shares of Stryker in a research report on Friday, January 9th. Thirteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $426.47.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.